Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesShire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09
Shire plc, the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of DAYTRANA in adolescents aged 13 to 17 years diagnosed with Attention–Deficit/Hyperactivity Disorder. In addition, data regarding the pharmacokinetic profile of DAYTRANA in children and adolescents was also presented. DAYTRANA, the first and only patch for the treatment of ADHD, is indicated for use in children aged 6 to 12 years with the disorder.
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Clinical Pharmacokinetics, 11/24/09
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Safety Profile, Pharmacokinetics, and Pharmacodynamics of Siplizumab, A Humanized Anti-CD2 Monoclonal Antibody, in Renal Allograft Recipients
Transplantation Proceedings, 11/20/09
Sponsor
Article Search
Sponsor